Association of rs712 polymorphism in a let-7 microRNA-binding site of KRAS gene with colorectal cancer in a Mexican population

• Main Authors: Gallegos Martha Patricia, Guillermo Moisés Zúñiga-González, Karen Gómez-Mariscal, Mónica Alejandra Rosales-Reynoso, Luis E Figuera, Ana María Puebla-Pérez, Tomas Pineda-Razo
• Format: Article
• Language: English
• Published: Mashhad University of Medical Sciences 2019-03-01
• Series: Iranian Journal of Basic Medical Sciences
• Subjects: Colorectal cancer; KRAS; let-7; Mexican population; Polymorphism
• Online Access: http://ijbms.mums.ac.ir/article_12147_eb65049ef21eb3b73b9f24d8721061d8.pdf
• ISSN: 2008-3866; 2008-3874

Objective(s): The rs712 polymorphism in a let-7 microRNA-binding site at KRAS gene has been associated with cancer. To examine its association with rs712 polymorphism, we analyzed Mexican individuals with colorectal cancer (CRC) and healthy subjects. Materials and Methods: Genotyping of the rs712 polymorphism was performed by polymerase chain reaction in 281 controls and 336 CRC patients. Results: The observed frequencies of rs712 polymorphism indicated an associated protective factor for CRC (P=0.032). An association between genotype and the disease was evident in: colon localization (allele T, odds ratio (OR) 3.82, 95% confidence Intervals (CI) 2.77-5.28, P=0.0001), node metastasis (genotype TT, OR 2.49, 95% CI 1.45-4.28, P=0.0009), poor differentiation (genotype GT, OR 2.35, 95% CI 1.35-4.1, P=0.0033), and poor chemotherapy response (genotype GT, OR 2.6, 95% CI 1.7-4.24, P=0.0001). Conclusion: Comparison of the data from patients with control group showed that polymorphism of rs712 in KRAS gene was protective factor, which was associated with susceptibility for CRC. However, the genotypes TT and GT of rs712 polymorphism in KRAS could contribute significantly to colon localization, node metastasis, poor differentiation and poor chemotherapy response in CRC patients in this sample population.